Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel
DOI:
https://doi.org/10.33393/grhta.2024.3107Keywords:
Assessment, Innovativeness, Medicines, Negotiation, Price and Reimbursement, RecommendationsAbstract
This paper illustrates the recommendations of a Working Group (WG) on the assessment of drugs innovativeness and the negotiation of price and reimbursement. The WG included researchers, institutions, clinicians, patient representatives and pharmaceutical companies.
The first part of the contribution summarizes the literature on drug pricing models, which was considered in the WG, and, in particular, the pricing criteria, the evaluation and negotiation processes, the management of the uncertainty of the evidence, the use of cross-reference pricing and price negotiation for new indications of existing drugs.
The second part illustrates the results of the WG with a focus on innovativeness assessment, value framework and price negotiation. The main recommendations of the WG are: to define more specific criteria for the identification of comparators and endpoints for macro therapeutic areas/settings; to produce guidelines on the use of indirect comparisons and studies supporting this evidence; to consider the drug value as the main driver of price and reimbursement negotiation; to maintain flexibility in the negotiation process, but, at the same time, to give greater structure and predictability in the assessment of value for money, with a more qualified role of cost-effectiveness and a range of threshold values for the incremental cost-effectiveness ratio; to selectively reintroduce Managed Entry Agreements and the Indication-based pricing model; to implement an early dialogue between the Italian Medicine Agency and the pharmaceutical companies in order to optimize the negotiation process, and a structured involvement of scientific societies and patient representatives.
Downloads
References
Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy. 2007;82(3):330-339. https://doi.org/10.1016/j.healthpol.2006.11.004 PMID:17125881 DOI: https://doi.org/10.1016/j.healthpol.2006.11.004
Kleijnen S, Lipska I, Leonardo Alves T, et al. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. Ann Oncol. 2016;27(9):1768-1775. https://doi.org/10.1093/annonc/mdw233 PMID:27329251 DOI: https://doi.org/10.1093/annonc/mdw233
Panteli D, Arickx F, Cleemput I, et al. Pharmaceutical regulation in 15 European countries review. Health Syst Transit. 2016;18(5):1-122. PMID:27929376
Jommi C, Armeni P, Costa F, Bertolani A, Otto M. Implementation of Value-based Pricing for Medicines. Clin Ther. 2020;42(1):15-24. https://doi.org/10.1016/j.clinthera.2019.11.006 PMID:31882225 DOI: https://doi.org/10.1016/j.clinthera.2019.11.006
Vogler S, Paris V, Ferrario A, et al. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Appl Health Econ Health Policy. 2017;15(3):307-321. https://doi.org/10.1007/s40258-016-0300-z PMID:28063134 DOI: https://doi.org/10.1007/s40258-016-0300-z
Garner S, Rintoul A, Hill SR. Value-Based Pricing: L’Enfant Terrible? PharmacoEconomics. 2018;36(1):5-6. https://doi.org/10.1007/s40273-017-0567-4 PMID:29270834 DOI: https://doi.org/10.1007/s40273-017-0567-4
Jommi C, Bertolani A, Armeni P, Costa F, Otto M. Pharmaceutical pricing and managed entry agreements: an exploratory study on future perspectives in Europe. Health Policy Technol. 2023;12(3):100771. https://doi.org/10.1016/j.hlpt.2023.100771 DOI: https://doi.org/10.1016/j.hlpt.2023.100771
Suresh P, Basu PK. Improving Pharmaceutical Product Development and Manufacturing: Impact on Cost of Drug Development and Cost of Goods Sold of Pharmaceuticals. J Pharm Innov. 2008;3(3):175-187. https://doi.org/10.1007/s12247-008-9043-1 DOI: https://doi.org/10.1007/s12247-008-9043-1
Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M. How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. PharmacoEconomics. 2021;39(11):1243-1269. https://doi.org/10.1007/s40273-021-01065-y PMID:34368939 DOI: https://doi.org/10.1007/s40273-021-01065-y
Rennane S, Baker L, Mulcahy A. Estimating the Cost of Industry Investment in Drug Research and Development: A Review of Methods and Results. Inquiry. 2021;58. https://doi.org/10.1177/00469580211059731 PMID:35170336 DOI: https://doi.org/10.1177/00469580211059731
Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020;18(1):31. https://doi.org/10.1186/s12962-020-00223-x PMID:32908456 DOI: https://doi.org/10.1186/s12962-020-00223-x
Light DW, Warburton R. Demythologizing the high costs of pharmaceutical research. Biosocieties. 2011;6(1):34-50. https://doi.org/10.1057/biosoc.2010.40 DOI: https://doi.org/10.1057/biosoc.2010.40
Schippers I, de Haan E, Cowan R. Overpriced - Drugs Developed with Dutch Public Funding. SOMO- Report 2019 Amsterdam. Online https://www.somo.nl/nl/wp-content/uploads/sites/2/2019/05/Report-Overpriced-def.pdf, (Accessed April 2024)
Schmidt L; Wild C. Assessing the Public and Philanthropic Financial Contribution to the Development of New Drugs: A Bibliographic Analysis. Sci. Technol. Public Policy 2020, 4(1), 8-14. doi: 10.11648/j.stpp.20200401.12 DOI: https://doi.org/10.11648/j.stpp.20200401.12
Rand LZ, Kesselheim AS. International reference pricing for prescription drugs: a landscape analysis. J Manag Care Spec Pharm. 2021;27(9):1309-1313. https://doi.org/10.18553/jmcp.2021.27.9.1309 PMID:34464208 DOI: https://doi.org/10.18553/jmcp.2021.27.9.1309
Gill J, Fontrier AM, Kyriopoulos D, Kanavos P. Variations in external reference pricing implementation: does it matter for public policy? Eur J Health Econ. 2019;20(9):1375-1397. https://doi.org/10.1007/s10198-019-01100-y PMID:31444673 DOI: https://doi.org/10.1007/s10198-019-01100-y
Morgan SG, Bathula HS, Moon S. Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ. 2020;368:l4627. https://doi.org/10.1136/bmj.l4627 PMID:31932289 DOI: https://doi.org/10.1136/bmj.l4627
Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. South Med Rev. 2012;5(1):38-46. PMID:23093898 DOI: https://doi.org/10.2174/1876824501305010001
Riccaboni M, Swoboda T, Van Dyck W. Pharmaceutical net price transparency across european markets: insights from a multi-agent simulation model. Health Policy. 2022;126(6):534-540. https://doi.org/10.1016/j.healthpol.2022.03.013 PMID:35459584 DOI: https://doi.org/10.1016/j.healthpol.2022.03.013
Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward. OECD Health Working Papers, 2019, No. 115, OECD Publishing, Paris. Online https://www.oecd.org/health/health-systems/pharma-managed-entry-agreements.htm (Accessed April 2024)
Morel T, Arickx F, Befrits G, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis 2013;24;8:198.DOI: https://doi.org/10.1186/1750-1172-8-198 PMID: 24365263 DOI: https://doi.org/10.1186/1750-1172-8-198
Carlson JJ, Chen S, Garrison LP Jr. Performance-Based Risk-Sharing Arrangements: An Updated International Review. PharmacoEconomics. 2017;35(10):1063-1072. https://doi.org/10.1007/s40273-017-0535-z PMID:28695544 DOI: https://doi.org/10.1007/s40273-017-0535-z
Jommi C. Chapter 4 - Managed Entry Agreements and High Cost Medicines (European Perspective), in Zaheer- Ud-Din Babar (ed.). Equitable Access to High-Cost Pharmaceuticals, Springer, London.2018; 35-49 DOI: https://doi.org/10.1016/B978-0-12-811945-7.00004-X DOI: https://doi.org/10.1016/B978-0-12-811945-7.00004-X
Antonanzas F, Juárez-Castelló C, Lorente R, Rodríguez-Ibeas R. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments. PharmacoEconomics. 2019;37(12):1469-1483. https://doi.org/10.1007/s40273-019-00838-w PMID:31535280 DOI: https://doi.org/10.1007/s40273-019-00838-w
Whittal A, Jommi C, De Pouvourville G, et al. Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework - Corrigendum. Int J Technol Assess Health Care. 2022;38(1):e43. https://doi.org/10.1017/S0266462322000290 PMID:35607832 DOI: https://doi.org/10.1017/S0266462322000290
Xoxi E, Rumi F, Kanavos P, et al. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems. Front Med Technol. 2022;4:888404. https://doi.org/10.3389/fmedt.2022.888404 PMID:35782579 DOI: https://doi.org/10.3389/fmedt.2022.888404
Campillo-Artero C, Puig-Junoy J, Segú-Tolsa JL, Trapero-Bertran M. Price Models for Multi-indication Drugs: A Systematic Review. Appl Health Econ Health Policy. 2020;18(1):47-56. https://doi.org/10.1007/s40258-019-00517-z PMID:31523756 DOI: https://doi.org/10.1007/s40258-019-00517-z
Rossini EE, Galeone C, Lucchetti C, Jommi C. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy. PharmacoEconom Open. 2024;8(2):251-261. https://doi.org/10.1007/s41669-023-00467-2 PMID:38228997 DOI: https://doi.org/10.1007/s41669-023-00467-2
Wang T, McAuslane N, Gardarsdottir H, Goettsch WG, Leufkens HGM. Building HTA insights into the drug development plan: current approaches to seeking early scientific advice from HTA agencies. Drug Discov Today. 2022;27(1):347-353. https://doi.org/10.1016/j.drudis.2021.09.014 PMID:34597755 DOI: https://doi.org/10.1016/j.drudis.2021.09.014
Wang T, McAuslane N, Liberti L, Leufkens H, Hövels A. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions. Value Health. 2018;21(6):707-714. https://doi.org/10.1016/j.jval.2017.11.003 PMID:29909876 DOI: https://doi.org/10.1016/j.jval.2017.11.003
EFPIA. (2023). Patients W.A.I.T. Indicator 2022 Survey. Online https://www.efpia.eu/media/s4qf1eqo/efpia_patient_wait_indicator_final_report.pdf (Accessed April 2024)
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.
Accepted 2024-06-14
Published 2024-07-15
